Board of Directors

Board of Directors

The highest decision-making body of the RIGHT Fund, comprising global health experts and
management professionals.
As an important complement to this role, the Board applies self-governance to ensure that it is functioning
in a manner that enables responsible and unbiased resolutions for the benefit of the RIGHT Fund.


Myongsei Sohn

Ex-Officio Member

Younbeen Kim

Younbeen Kim is the Executive Director of the RIGHT Fund. Soon after completing her studies and licensures in pharmacy, she embarked on a 10-year-long marketing career within the pharmaceutical industry –beginning at Servier Laboratories, followed by Bayer Diagnostics, and culminating with a move to Novartis in 2003. Upon joining Novartis she quickly advanced into upper management as the Marketing Director of Infectious Disease and Transplant Business Franchises in 2004. Ms. Kim then made a significant career transition from Marketing into Partnerships and Research Funds by spearheading the launch of the Novartis Venture Fund in Korea in 2006. She then transitioned to an international position as the Head of Partnerships & Research Operations of the Novartis Institute for Tropical Diseases (NITD) in Singapore from 2009 to 2017. In this capacity she established research networks at both the regional and international level.

Ex-Officio Member

In-taek Lim

Director General for Health Industry of the Korean Ministry of Health and Welfare

Ex-Officio Member

Sungsoon Kim

Dr. Kim now serves as the Director General of the Center for Infectious Disease Research at the National Institute of Health(KNIH), Korea Center for Disease Control & Prevention(KCDC). Since Dr. Kim had gained(earned) a her PhD in HIV/AIDS research from Ewha Women’s university, she has worked in KNIH/KCDC as a scientist in field of infectious disease for more than 30 years. The highlights of her experience include : a leadership within the Center for Infectious Disease, KNIH/KCDC and KFDA.

- leading the study in field of TB & Bacterial respiratory disease, Zoonotic Disease, and CJD as a director for Bacterial research division as well as focusing on study for the development of vaccine candidates needed for public sectors such as TB vaccine as a director for Vaccine research division
- Responsible conductor of WHO CC for standardization and evaluation of biologics and 21 WHO CC members in Korea as a director of biologics Research Division in KFDA
- Acting on role as a national control tower for MERS diagnosis, pathogen study in 2015 as a director for viral respiratory research division
- Working in the research field for HIV & chronic viral disease over 25 years
- Dr Kim has served on various committees and in various leadership capacities within domain of infectious diseases such as IRB committee for KCDC and KFDA, National Bank for pathogen culture & collection and Vice president at Korean AIDS Society. She has been active in research throughout her career and has so far published more than 100 articles in various journals and registered 20 patents.

Member at large

Glenn Rockman

Mr. Rockman is currently a partner at Global Health Investment Fund (GHIF). Mr. Rockman earned an AB in Public Policy from the Woodrow Wilson School of Public & International Affairs at Princeton University. He originally joined GHIF in 2014 after 11 years in investment banking at J.P. Morgan, where he focused on raising capital for non-profit organizations and social enterprises. Mr. Rockman also serves as a director on a number of corporate boards, including EuBiologics (Republic of Korea), Themis Bioscience (Austria), Tribendimidine Finance Company (US), IanTech (US), and Univercells SA (Belgium). He is also a champion of innovative financing mechanisms for global health technologies, advocating for new sources of funding and new incentive models to catalyze expanded investment flows into product development for neglected indications.

Member at large

Kim Bush

Mr. Bush is a Senior Healthcare Executive with a strong science background and successful track record of building and leading multiple global healthcare businesses in the private sector and in building strategic alliances and partnerships in Global Health. He has held multiple Director level assignments within such organizations as: the Bill and Melinda Gates Foundation, Baxter International Healthcare Corporation, and the American Hospital Supply Corporation. Mr. Bush is proficient at establishing and implementing strategies to drive growth and profitability of new and existing ventures and served 3 years with the U.S. Academies of Sciences on the Forum on Public-Private Partnerships on Global and Health and Safety. He has a deep and far-reaching familiarity with international, private, nonprofit (NGO) and government market dynamics. Experienced and effective in both traditional and highly matrixed business environments, he is currently a valued member of the RIGHT Fund’s Board of Directors.

Member at large

Peter Hotez

Professor Dr. Hotez is an internationally-recognized physician-scientist in neglected tropical diseases and vaccine development. He currently the Dean of the National School of Tropical Medicine and Professor of Pediatrics and Molecular Virology & Microbiology at Baylor College of Medicine; where he is also the Director of the Texas Children’s Center for Vaccine Development (CVD) and Texas Children’s Hospital Endowed Chair of Tropical Pediatrics. He is also a University Professor at Baylor University, and a Fellow in Disease and Poverty at the James A Baker III Institute for Public Policy. Additionally, Dr. Hotez serves as an elected member of the National Academy of Medicine and in 2018 he was appointed by the US State Department to serve on the Board of Governors for the US-Israel Binational Science Foundation. He was also elected to the American Academy of Arts and Sciences. The RIGHT Fund is now honored to have him serve on our Board of Directors.

Ex-Officio Observer

Andrin Oswald

Director, Life Science Partnerships, Bill & Melinda Gates Foundation